Literature DB >> 14760797

Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies.

David P D'Cruz1, Susana Mellor-Pita, Beatriz Joven, Giovanni Sanna, Judith Allanson, James Taylor, Munther A Khamashta, Graham R V Hughes.   

Abstract

OBJECTIVE: Transverse myelitis (TM) is a rare complication of systemic lupus erythematosus (SLE). Although usually a late manifestation of SLE, it can occur at presentation. We investigated the clinical presentation, treatment and outcome of 15 patients with TM as the presenting manifestation of SLE or lupus-like disease.
METHODS: All patients received corticosteroids, while 13 also received immunosuppressive therapy. Five patients were fully anticoagulated with warfarin.
RESULTS: A sensory level with spastic lower limb weakness and sphincter disturbance was the most common presentation: 14/15 patients had a thoracic or cervical sensory level. Cerebrospinal fluid examination showed high protein concentrations in 3 patients and oligoclonal bands in 8. Eleven of the 15 (73%) had antiphospholipid antibodies (aPL). Of the 15 patients, 3 had complete resolution of the symptoms, 6 had good functional improvements, 5 had good to fair outcome with some functional deficit, and one patient who received corticosteroids alone later died from pneumonia.
CONCLUSION: We describe 15 patients with TM as the presenting manifestation of SLE or lupus-like disease with a high prevalence of aPL. Our data support the view that early diagnosis and immunosuppressive therapy may be superior to corticosteroids alone in improving functional outcome. In those patients with aPL, antiplatelet agents and/or warfarin should also be considered.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14760797

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  38 in total

Review 1.  Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations.

Authors:  George K Bertsias; Dimitrios T Boumpas
Journal:  Nat Rev Rheumatol       Date:  2010-05-11       Impact factor: 20.543

Review 2.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

3.  Initial presentation of acute transverse myelitis in systemic lupus erythematosus: demographics, diagnosis, management and comparison to idiopathic cases.

Authors:  Steffan W Schulz; Max Shenin; Amy Mehta; Amal Kebede; Marshall Fluerant; Chris T Derk
Journal:  Rheumatol Int       Date:  2011-07-22       Impact factor: 2.631

4.  SLE-associated transverse myelitis successfully treated with Rituximab (anti-CD20 monoclonal antibody).

Authors:  D J Armstrong; M T McCarron; G D Wright
Journal:  Rheumatol Int       Date:  2005-10-18       Impact factor: 2.631

5.  Hemorrhagic acute disseminated encephalomyelitis as first manifestation of systemic lupus erythematosus.

Authors:  Pedro Emilio Bermejo; Angel Ruiz; Maite Beistegui; Juan Antonio Zabala; Carlos Escamilla
Journal:  J Neurol       Date:  2008-04-23       Impact factor: 4.849

Review 6.  Lupoid sclerosis.

Authors:  Briele Keiserman; Luiz Fernando Garcias da Silva; Mauro W Keiserman; Carlos Alberto von Mühlen; Henrique Luiz Staub
Journal:  Rheumatol Int       Date:  2009-10-14       Impact factor: 2.631

7.  Serum anticardiolipin antibodies in patients with neuromyelitis optica spectrum disorder.

Authors:  Youming long; Yihua He; Yangbo Zheng; Mengyu Chen; Bin Zhang; Cong Gao
Journal:  J Neurol       Date:  2013-12       Impact factor: 4.849

8.  Lupus or syphilis? That is the question!

Authors:  Joana Azevedo Duarte; Celia Coelho Henriques; Carolina Sousa; José Delgado Alves
Journal:  BMJ Case Rep       Date:  2015-06-04

9.  Manifestations of systemic lupus erythematosus.

Authors:  Manole Cojocaru; Inimioara Mihaela Cojocaru; Isabela Silosi; Camelia Doina Vrabie
Journal:  Maedica (Buchar)       Date:  2011-10

10.  Transverse myelitis as a presenting feature of late onset systemic lupus erythematosus.

Authors:  Hani Almoallim; Majidah Bukhari; Leena Alwafi; Gassan Wali
Journal:  Ann Saudi Med       Date:  2009 Mar-Apr       Impact factor: 1.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.